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Introduction: Recent pivotal phase III studies in patients with
advanced non-small cell lung cancer (NSCLC) consistently showed
greater survival benefit of pemetrexed in patients with nonsquamous
cell carcinoma histology (nonsquamous histology) compared with
those with squamous cell carcinoma histology (squamous histol-
ogy). To confirm the efficacy differences of pemetrexed by histo-
logic type, we conducted an additional subgroup analysis of data
from a Japanese randomized phase II study evaluating the efficacy
and safety of pemetrexed 500 mg/m2 (P500) and 1000 mg/m2
(P1000) in patients with advanced NSCLC previously treated with
chemotherapy. The efficacy and safety results of original phase II
study have already been reported (Ohe et al., Clin Cancer Res
2008;14:4206–4212).
Methods: Objective response rates (ORRs), overall survival time,
and progression-free survival time were analyzed by subgroup of
histology, squamous, and nonsquamous, for the dose groups com-
bined and separately.
Results: A total of 216 patients were evaluable for efficacy. One
hundred sixty-eight patients had nonsquamous and 48 had squamous
histology. ORRs were 20.8% and 2.1% (p  0.001); median sur-
vival times (MST) were 16.0 and 8.5 months (p  0.001); and
median progression-free survival times (PFS) were 3.1 and 1.6
months (p  0.001) for nonsquamous and squamous histology,
respectively. In patients who were randomized to the P500 group,
ORR were 23.5% and 0% (p  0.0062); MST were 19.4 and 7.9
months (p  0.001); and PFS were 3.1 and 1.4 months (p  0.001)
for nonsquamous and squamous histology, respectively. In patients
who were randomized to the P1000 group, ORR were 18.1% and
4.0% (p  0.1113); MST were 13.5 months and 8.6 months (p 
0.0971); and PFS were 3.1 and 1.7 months (p  0.0024) for
nonsquamous and squamous histology, respectively. There were no
clinically relevant differences in the incidence of toxicities between
histology groups.
Conclusions: This study showed the difference of pemetrexed
efficacy by histologic type, and this result supports the treatment-
by-histology effect observed in the past pivotal phase III studies.
Higher dose of pemetrexed resulted in similar outcomes both in
patients with nonsquamous histology and squamous histology. Pem-
etrexed is not as effective as alternative therapies for previously
treated squamous histology; however, pemetrexed should be the key
agent for the treatment of patients with nonsquamous histology.
Key Words: Pemetrexed, Non-small cell lung cancer, Nonsqua-
mous, Squamous, Histology.
(J Thorac Oncol. 2009;4: 1530–1536)
Two-drug combinations of the third-generation agents (do-cetaxel, paclitaxel, gemcitabine, and vinorelbine) with a
platinum compound have been considered the standard treat-
ment option for advanced non-small cell lung cancer
(NSCLC) based on several randomized studies.1–3 Histology
has not been consistently reported as prognostic or predictive
for outcomes with cytotoxic cancer chemotherapy in ad-
vanced NSCLC, until publication of a large phase III study
using cisplatin and pemetrexed.4
Pemetrexed is an inhibitor of thymidylate synthase,
resulting in decreased thymidine necessary for pyrimidine
synthesis, which is the primary mechanism of action.5,6 Pem-
etrexed also inhibits dihydrofolate reductase and glycinamide
ribonucleotide formyl transferase, the latter of which is a
folate-dependent enzyme involved in purine synthesis. Un-
like other classic antifolates, pemetrexed has a unique pyrro-
lopyrimidine nucleus and can inhibit multiple folate-depen-
dent enzymes.
The phase III study comparing cisplatin plus gemcitab-
ine with cisplatin plus pemetrexed in chemotherapy-naive
patients with advanced NSCLC demonstrated noninferiority
of cisplatin plus pemetrexed to cisplatin plus gemcitabine in
the overall study population, with significantly less febrile
neutropenia, anemia, thrombocytopenia, and alopecia favor-
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ing cisplatin plus pemetrexed.4 This study showed that over-
all survival was statistically superior for cisplatin plus pem-
etrexed in patients with nonsquamous histology. In contrast,
survival was shorter for cisplatin plus pemetrexed compared
with cisplatin plus gemcitabine in patients with squamous cell
carcinoma. This was the first phase III study in NSCLC that
prospectively demonstrated survival differences for chemo-
therapy based on histologic type.
In the subgroup analysis of the phase III study, which
compared pemetrexed alone with docetaxel in patients with
NSCLC previously treated with chemotherapy, also dem-
onstrated that overall survival was significantly longer for
pemetrexed versus docetaxel in patients with nonsquamous
histology, whereas conversely, survival was shorter for
pemetrexed compared with docetaxel in patients with
squamous histology.7
On the basis of these phase III results, we conducted an
additional subgroup analysis of data from a Japanese phase II
study, which randomized previously treated patients with
NSCLC to pemetrexed 500 mg/m2 (P500) or 1000 mg/m2
(P1000) to further examine efficacy differences for pemetrexed
by histology. The efficacy and safety results of original phase II
study have already been reported8; Figure 1 shows the trial
design and efficacy data of this phase II study. Of the 216
patients evaluable for efficacy (108 in each arm), response rates
were18.5% (90% confidence interval, 12.6–25.8%) and 14.8%
(90% confidence interval, 9.5–21.6%), median survival times
(MSTs) were 16.0 and 12.6 months, 1-year survival rates were
59.2% and 53.7%, and median progression-free survival were
3.0 and 2.5 months for the P500 and P1000, respectively.
Drug-related toxicity was generally tolerable for both doses.
PATIENTS AND METHODS
Trial Design
We analyzed the data from the randomized, open-label,
multicenter study8 in which patients were registered through
the central registration system. Two hundred forty-four pa-
tients with advanced NSCLC previously treated with chemo-
therapy at 28 medical institutions in Japan were registered
between October 2004 and October 2005, and 226 patients
were randomized to receive either pemetrexed 500 mg/m2
(P500) or 1000 mg/m2 (P1000) (Figure 1). The randomization
was done by an independent registration center and was
dynamically balanced for Eastern Cooperative Oncology
Group performance status (PS), previous platinum chemo-
therapy, disease stage, gender, a time from prior chemother-
apy to the enrollment, and hospital. Patients were balanced
with respect to the study drug in each stratum for each
prognostic factor using the minimization method. The pri-
mary end point was response rate, and the secondary end
points included overall survival time, progression-free sur-
vival time, and incidence of toxicities.
The sample size was calculated to ensure that the
response rate in each group exceeded 5%.8 The study was
conducted in accordance with the ethical principles stated
in the Declaration of Helsinki after being approved by the
institutional review board of individual hospitals. Pri-
mary results of this trial and further details regarding the
study design and statistical analyses have been published
previously.8
Patients and Treatment
Patients who satisfied all of the following criteria were
included into the study8: age 20 to 75 years, performance
status 0 to 2, stage III or IV diagnosed by images before the
registration to this study, NSCLC confirmed by histology or
cytology, at least one measurable tumor according to the
Response Evaluation Criteria in Solid Tumor (RECIST cri-
teria),9 previously received one or two chemotherapy regi-
mens for NSCLC, adequate organ function, life expectancy of
at least 12 weeks, and written consent to participate in the
study. Histologic subtypes outcome of NSCLC were exam-
ined in each institution.
Randomization*
n = 244
Pemetrexed 500 mg/m2   Day 1, q3w
Pemetrexed 1000 mg/m2 Day 1, q3w
Patients who received at least one dose of P500: n = 114
Patients included in efficacy analysis: n = 108
RR = 18.5%; MST = 16.0 months
Patients who received at least one dose of P1000: n = 112**
Patients included in efficacy analysis: n = 108
RR = 14.8%, MST = 12.6 months
FIGURE 1. Trial design and efficacy data. From phase II randomized study.8 NSCLC, non-small cell lung cancer; ECOG, Eastern
Cooperative Oncology Group; PS, performance status; q, every; w, weekly; n, number of patients; RR, response rate; MST, median
survival time. *Patients: stage IIIB/IV NSCLC, 1 to 2 prior chemotherapeutic regimens, and ECOG PS 0 to 2; Stratified by: gender,
ECOG PS, disease stage, platinum use, time for prechemotherapy, and study site. **One patient was excluded from statistical analy-
sis because the data of this patient was not available.
Journal of Thoracic Oncology • Volume 4, Number 12, December 2009 Efficacy Differences of Pemetrexed by Histology
Copyright © 2009 by the International Association for the Study of Lung Cancer 1531
Patients were randomly allocated to either pemetrexed
500 mg/m2 (P500) arm or pemetrexed 1000 mg/m2 (P1000)
arm. Pemetrexed was administered as an intravenous, 10-
minute infusion on day 1 of a 21-day cycle. Patients were
instructed to take orally 1 g/d of a multivitamin containing
500 g folic acid from at least 7 days before the day 1 of
cycle 1 until 22 days after the last administration of pem-
etrexed. Vitamin B12 (1000 g) was injected intramuscularly,
at least 7 days before the day 1 of cycle 1 and repeated every
9 weeks until 22 days after the last administration of
pemetrexed.
Assessments
The antitumor effect of pemetrexed was evaluated
based on the RECIST criteria. Response rate represented the
percentage of patients whose best overall response had been
either complete response or partial response. Survival time
was defined as the period from the registered date of first
administration until the date of death regardless of the cau-
sality with pemetrexed. Progression-free survival time was
defined as the period from the registered date of first admin-
istration until the day on which progressive disease was
determined or the date of death regardless of the causality
with pemetrexed. All adverse events were graded based on
the Common Terminology Criteria for Adverse Events, ver-
sion 3.0.
Statistical Analysis
Of 226 patients enrolled in the study, the efficacy
analysis included 216 patients who satisfied all the inclusion
criteria, did not meet any of the exclusion criteria, and
received at least one dose of pemetrexed. The safety analysis
included 225 patients who received at least one dose of
pemetrexed.
Efficacy and safety results were analyzed by histology
for the dose groups combined and separately. Response rates,
disease control rates, overall survival time, and progression-
free survival time were compared between the histologic
types (nonsquamous and squamous histology) for the P500
and P1000 arms combined and separately. Differences of
response rates were compared by using Fisher’s exact test. A
Kaplan-Meier method was used to estimate overall survival
time and progression-free survival time. Differences of time-
to-event distributions by histology were compared using a
log-rank test. A Cox proportional hazard model was used for
hazard ratio estimation (squamous/nonsquamous histology).
Two-sided significance level of 5% was used in all tests. In
the safety analysis, number of deaths, serious adverse events,
TABLE 1. Characteristics of Patients
Variable
Nonsquamous Squamous
P500 P1000 Total P500 P1000 Total
Patients who received at least 1 dose
of pemetrexed, n
89 85 174 25 26 51
Gender, n (%)
Female 40 (44.9) 36 (42.4) 76 (43.7) 2 (8.0) 4 (15.4) 6 (11.8)
Male 49 (55.1) 49 (57.6) 98 (56.3) 23 (92.0) 22 (84.6) 45 (88.2)
Age (yr)
Median 60 62 61 67 64 65
Range 37–74 26–74 26–74 58–74 50–74 50–74
ECOG PS, n (%)
0 34 (38.2) 29 (34.1) 63 (36.2) 11 (44.0) 8 (30.8) 19 (37.3)
1 50 (56.2) 51 (60.0) 101 (58.0) 13 (52.0) 17 (65.4) 30 (58.8)
2 5 (5.6) 5 (5.9) 10 (5.7) 1 (4.0) 1 (3.8) 2 (3.9)
Disease stage, n (%)
III 15 (16.9) 16 (18.8) 31 (17.8) 7 (28.0) 8 (30.8) 15 (29.4)
IV 74 (83.1) 69 (81.2) 143 (82.2) 18 (72.0) 18 (69.2) 36 (70.6)
No. of prior chemotherapy, n (%)
1 32 (36.0) 39 (45.9) 71 (40.8) 12 (48.0) 14 (53.8) 26 (51.0)
2 54 (60.7) 45 (52.9) 99 (56.9) 13 (52.0) 12 (46.2) 25 (49.0)
3 3 (3.4) 1 (1.2) 4 (2.3) 0 (0.0) 0 (0.0) 0 (0.0)
Prior platinum, n (%)
No 4 (4.5) 6 (7.1) 10 (5.7) 2 (8.0) 1 (3.8) 3 (5.9)
Yes 85 (95.5) 79 (92.9) 164 (94.3) 23 (92.0) 25 (96.2) 48 (94.1)
Interval from last prior chemotherapy,
n (%)
3 mo 31 (34.8) 34 (40.0) 65 (37.4) 11 (44.0) 11 (42.3) 22 (43.1)
3 mo 58 (65.2) 51 (60.0) 109 (62.6) 14 (56.0) 15 (57.7) 29 (56.9)
n, number of patients; P500, pemetrexed 500 mg/m2 arm; P1000, pemetrexed 1000 mg/m2 arm; ECOG PS, Eastern Cooperative
Oncology Group performance status.
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grade 2 adverse events, and grade 3/4/5 adverse events were
calculated separately for nonsquamous and squamous histol-
ogy in each dose group.
RESULTS
Patient Characteristics
Patient characteristics are shown by histology and dose
group (P500 or P1000) in Table 1. Total of 225 patients
received pemetrexed 500 mg/m2 or 1000 mg/m2 at least once
during the study. Baseline patient characteristics by histology
were well balanced between the two dose groups.
Efficacy
Results of the efficacy analysis (response rate, disease
control rate, overall survival time, and progression-free sur-
vival time) by histology for the dose groups combined are
summarized in Table 2. Kaplan-Meier curves for overall
survival time and progression-free survival time are shown in
Figures 2A, B, respectively. Response rates in patients with
nonsquamous and squamous histology were 20.8% (35/168)
and 2.1% (1/48) (p  0.001), and disease control rates in
patients with nonsquamous and squamous histology were
57.1% (96/168) and 29.2% (14/48) (p  0.001), respectively.
MSTs in patients with nonsquamous and squamous histology
were 16.0 and 8.5 months (hazard ratio, 2.11; log-rank test,
p  0.001), and median progression-free survival times were
3.1 and 1.6 months (hazard ratio, 2.19; log-rank test, p 
0.001), respectively.
Results of the efficacy analysis (response rate, overall
survival time, and progression-free survival time) by histol-
ogy for each dose group are summarized in Table 3. Kaplan-
Meier curves for overall survival time and progression-free
FIGURE 2. A, Kaplan-Meier curves for overall survival by histology. B, Kaplan-Meier curves for progression-free survival by
histology. MST, median survival time.





(n  48) p
Response rate (%) 20.8 2.1 0.001a







a Fisher’s exact test.
b Log-rank test.









(n  25) p
Response rate (%) 23.5 0.0 0.0062a 18.1 4.0 0.1113a
Disease control rate (%) 62.4 30.4 0.0088a 51.8 28.0 0.0419a
Overall survival
(median) (mo)
19.4b 7.9 0.001c 13.5 8.6 0.0971c
Progression-free survival
(median) (mo)
3.1 1.4 0.001c 3.1 1.7 0.0024c
Adjustment of multiplicity was not performed.
a Fisher’s exact test.
b Survival rate was 50.03%.
c Log-rank test.
P500, pemetrexed 500 mg/m2 arm; P1000, pemetrexed 1000 mg/m2 arm.
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survival time are shown in Figures 3A–D. Response rates of
nonsquamous and squamous histology patients were 23.5%
(20/85) and 0% (0/23) in P500 (p  0.0062) and 18.1%
(15/83) and 4.0% (1/25) in P1000 (p  0.1113). Disease
control rates of nonsquamous and squamous histology pa-
tients were 62.4% (53/85) and 30.4% (7/23) in P500 (p 
0.0088) and 51.8% (43/83) and 28.0% (7/25) in P1000 (p 
0.0419). In the P500 group, median overall survival time was
19.4 months in patients with nonsquamous histology (sur-
vival rate: 50.03%) and 7.9 months in patients with squamous
histology patients (incidence of events: 50.00%) (hazard
ratio, 2.90; log-rank test, p  0.001). In the P1000 group,
median overall survival time was 13.5 months in patients
with nonsquamous histology and 8.6 months in patients with
squamous histology (hazard ratio, 1.56; log-rank test, p 
0.0971). Median progression-free survival time was 3.1
months in patients with nonsquamous histology and 1.4
months in patients with squamous histology in the P500
group (hazard ratio, 2.23; log-rank test, p  0.001). In the
P1000 group, median progression-free survival time was 3.1
months in patients with nonsquamous histology and 1.7
months in patients with squamous histology (hazard ratio,
2.06; log-rank test, p  0.0024).
Safety
The safety of pemetrexed 500 mg/m2 and 1000 mg/m2
has been reported by Ohe et al.8 Major adverse events
occurred in the study participants are shown by dose group
(P500 and P1000) and histology in Table 4. Grade 3/4/5
pneumonitis regardless to causality with pemetrexed was
observed in two nonsquamous and two squamous histology
patients in the P500 group and one nonsquamous and two
squamous histology patients in the P1000 group. Toxicities
occurred in both dose groups were tolerable, and there were
no clinically relevant differences in the incidence of toxicities
by histology.
DISCUSSION
The results of subgroup analysis demonstrated efficacy
differences of pemetrexed by histology in pretreated patients
with advanced NSCLC. Objective response rate of pem-
etrexed was 20.8% in patients with nonsquamous histology
and only 2.1% in squamous histology patients. Overall sur-
vival and progression-free survival were significantly better
for patients with nonsquamous than squamous histology.
MST of 16.0 months in nonsquamous histology patients is
FIGURE 3. Kaplan-Meier curves for overall survival by dose and histology: (A) patients treated with pemetrexed 500 mg/m2 and
(B) patients treated with pemetrexed 1000 mg/m2. Kaplan-Meier curves for progression-free survival by dose and histology: (C) pa-
tients treated with pemetrexed 500 mg/m2 and (D) patients treated with pemetrexed 1000 mg/m2. MST, median survival time.
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encouraging in this situation. The efficacy of pemetrexed for
nonsquamous histology was shown in the recommended
dose of 500 mg/m2 and also in the higher dose of 1000
mg/m2. Higher dose of pemetrexed resulted in similar
outcomes both in patients with nonsquamous histology and
squamous histology.
The difference in survival benefit of pemetrexed be-
tween the histologic types may in part be explained by a
differential expression of thymidylate synthase, which is the
primary mechanism of actions. In specimens from chemona-
ive patients with early-stage NSCLC, expression of thymidy-
late synthase was observed to be elevated in squamous
histology compared with adenocarcinoma.10 A preclinical
study showed the overexpression of thymidylate synthase
was associated with the decreased in vitro sensitivity of
pemetrexed.11 Translational studies are needed to evaluate
biologic markers using clinical samples.
Pemetrexed was well tolerated in both the P500 and
P1000 arms,8 and also there were no clinically relevant differ-
ences in the toxicities between histologic groups. This is in
contrast to vascular endothelial growth factor inhibitors, e.g.,
bevacizumab, which have an increased risk of life-threatening
toxicities in patients with certain squamous cell lung tumors.
A randomized phase III trial designed to evaluate main-
tenance chemotherapy of pemetrexed versus placebo after
platinum-based chemotherapy demonstrated that progression-
free and overall survival were significantly longer with pem-
etrexed in patients with nonsquamous histology, whereas no
treatment advantage was observed in patients with squamous
histology.12,13 This is the third phase III study to demonstrate
efficacy differences by histology in the treatment of advanced
NSCLC.
It has been regarded that two drug combinations of
platinum agents with third generation agents have similar
efficacy.14,15 Gemcitabine-containing regimens showed sig-
nificant longer progression-free survival than nongemcitab-
ine-containing regimens in a meta-analysis.16 Thus, cispaltin
plus gemcitabine is one of the most active regimens for
NSCLC. However, the randomized trial comparing cisplatin
plus pemetrexed with cisplatin plus gemcitabine demon-
strated statistically significant survival benefit favoring cis-
platin plus pemetrexed in patients with nonsquamous histol-
ogy. Considering the consistent results of other studies4,17
using pemetrexed and favorable toxicity profile, cisplatin plus
pemetrexed should be a reference regimen in future trials for
patients with nonsquamous histology.
In conclusion, the results of subgroup analysis showed
the difference of pemetrexed efficacy by histologic type, and
this result supports the treatment-by-histology effect ob-
served in the past pivotal phase III studies. Higher dose of
pemetrexed resulted in similar outcomes both in patients
with nonsquamous histology and squamous histology.
Pemetrexed is not as effective as alternative therapies for
previously treated squamous histology, however, pem-
etrexed should be the key agent for the treatment of
patients with nonsquamous histology.
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TABLE 4. Major Hematologic and Nonhematologic Toxicity by Common Terminology Criteria for Adverse
Events Version 3.0a
P500 P1000
Nonsquamous (n  89) Squamous (n  25) Nonsquamous (n  85) Squamous (n  26)
Grade 2 Grade 3/4/5 Grade 2 Grade 3/4/5 Grade 2 Grade 3/4/5 Grade 2 Grade 3/4/5
Leukopenia 36.0 13.5 20.0 20.0 40.0 27.1 34.6 3.8
Neutropenia 28.1 21.3 16.0 20.0 29.4 28.2 23.1 11.5
Lymphopenia 31.5 6.7 24.0 40.0 25.9 25.9 34.6 7.7
Anemia 19.1 5.6 28.0 20.0 40.0 8.2 19.2 15.4
Thrombocytopenia 0 0 0 0 8.2 0 7.7 3.8
Nausea 16.9 1.1 16.0 4.0 17.6 3.5 7.7 3.8
Vomiting 9.0 1.1 8.0 0 10.6 3.5 15.4 0
Anorexia 19.1 2.2 8.0 12.0 15.3 14.1 11.5 19.2
Fatigue 2.2 1.1 8.0 0 4.7 1.2 3.8 11.5
Diarrhea 3.4 1.1 0 0 3.5 2.4 3.8 0
Constipation 9.0 1.1 0 0 5.9 3.5 7.7 3.8
Rash 51.7 3.4 44.0 0 63.5 5.9 61.5 0
Alopecia 0 0 0 0 0 0 0 0
Pneumonitis 1.1 2.2 4.0 8.0 0 1.2 0 7.7
AST 27.0 6.7 4.0 12.0 29.4 5.9 11.5 0
ALT 20.2 19.1 8.0 12.0 35.3 9.4 23.1 3.8
The values are given in percentage.
a Major adverse events of grade 2 or grade 3/4/5 are shown irrespective of causal relationship with pemetrexed.
P500, pemetrexed 500 mg/m2 arm; P1000, pemetrexed 1000 mg/m2 arm; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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